2022
DOI: 10.1002/epi4.12549
|View full text |Cite
|
Sign up to set email alerts
|

The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 24 publications
0
2
0
Order By: Relevance
“…Applying the modelling framework presented, the parameters optimised for each subject could serve as an in silico 'twin' on which pharmacological, as well as nonpharmacological, interventions could be trialled virtually to aid clinical decision-making. As an example, the findings at the group level from this cohort suggest that utilising antiseizure medication that specifically modulates excitatory synapses, such as perampanel (a known AMPA receptor antagonist [41,35]), could be beneficial for seizure control in children with focal lesional epilepsies. Further work will include assessing the use of the model on prospective data to see if it can predict the effects of interventions with known mechanisms.…”
Section: Digital Twinning To Facilitate Personalised Antiseizure Mana...mentioning
confidence: 94%
See 1 more Smart Citation
“…Applying the modelling framework presented, the parameters optimised for each subject could serve as an in silico 'twin' on which pharmacological, as well as nonpharmacological, interventions could be trialled virtually to aid clinical decision-making. As an example, the findings at the group level from this cohort suggest that utilising antiseizure medication that specifically modulates excitatory synapses, such as perampanel (a known AMPA receptor antagonist [41,35]), could be beneficial for seizure control in children with focal lesional epilepsies. Further work will include assessing the use of the model on prospective data to see if it can predict the effects of interventions with known mechanisms.…”
Section: Digital Twinning To Facilitate Personalised Antiseizure Mana...mentioning
confidence: 94%
“…We focused on perturbing the conductance parameters because these parameters represent a key mechanistic target of antiseizure medications (for example, see [33]). This includes benzodiazepines, which have been shown to increase the conductance of GABA A (inhibitory) channels [34] and perampanel, which is known to block AMPA (excitatory) mediated synaptic conductances [35]. Hence, to simulate the effects of treatment, we decreased the excitatory and leak conductances and increased the inhibitory and KNa conductances in models derived from patient data.…”
Section: In Silico Prediction For Interventionmentioning
confidence: 99%
“…A third-generation ASD, perampanel (PER), recently gained attention as it was shown to significantly reduce the seizure frequency of previously drug-refractory GBM-related seizures (Vecht et al, 2017 ; Dunn-Pirio et al, 2018 ; Izumoto et al, 2018 ; Coppola et al, 2020 ; Maschio et al, 2020 ). Its anti-seizure effects are mediated by its actions as a non-competitive AMPARs antagonist (Hanada et al, 2011 ; Frampton, 2015 ; Augustin et al, 2018 ; Brito da Silva et al, 2021 ). PER exhibits significant anti-proliferative effects on multiple GBM cell lines at various concentrations, and appears to reduce the overall concentration of extracellular glutamate (Lange et al, 2019 ; Salmaggi et al, 2021 ).…”
Section: From Laboratory To Clinical Translationmentioning
confidence: 99%
“…In addition, human brain slices provides an ideal ex vivo electrophysiological platform to allow novel and established compounds to be tested on activity associated with refractoriness. This approach allows an assessment of target engagement and efficacy (Brito da Silva et al., 2021) prior to conducting complex and costly clinical trials.…”
Section: In Vitro Brain Slices – a Powerful Tool For Neurophysiologic...mentioning
confidence: 99%